---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-016671"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2022-06-14T23:59:59+00:00"
generated_at: "2026-06-25T01:51:39.418944+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma shareholders approve all proposals including authorized share reduction and 2022 Omnibus Incentive Plan

## Summary
- Elected directors Breen, Shrotriya, and Wendel with majority support (for votes 58-61% of shares present).
- Ratified Weinberg & Company as independent auditor for FY2022 (19.7M for, 0.2M against).
- Approved 2022 Omnibus Incentive Plan authorizing up to 5M shares of common stock.
- Approved amendment to reduce authorized common stock from 750M to 250M shares (19.6M for).
- Advisory say-on-pay passed (63.7% of votes cast) and frequency set at 1 year (11.9M for).

## SEC filing metadata
- accession: 0001493152-22-016671
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2022-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315222016671/0001493152-22-016671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315222016671/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-016671
- JSON: https://secwatch.observer/filing/0001493152-22-016671.json
- Plain text: https://secwatch.observer/filing/0001493152-22-016671.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.